Clinical Scorecard: Multivitamins After MI: Any Benefit for Patients with Diabetes?
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: Multivitamins After MI |
| Key Mechanisms | High-dose oral multivitamins and multiminerals (OMVM) supplementation does not reduce major adverse cardiovascular events. |
| Target Population | Population described in the source article. |
| Care Setting | Care setting described in the source article. |
Key Highlights
- No reduction in major adverse cardiovascular events with high-dose OMVM.
- 35% of participants experienced primary endpoint events in both OMVM and placebo groups.
- Secondary outcome showed no significant difference in MI, stroke, or cardiovascular death.
- High adherence rate of 91.4% in the OMVM group.
- Numerically higher MI, stroke, and cardiovascular mortality observed in the OMVM group, but not statistically significant.
Guideline-Based Recommendations
Diagnosis
Management
- High-dose OMVM supplementation is not recommended for reducing cardiovascular events in this population based on trial findings.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with diabetes and a history of myocardial infarction aged 50 years or older
High-dose OMVM does not provide cardiovascular benefits.
Clinical Best Practices
- Consider alternative management strategies for cardiovascular risk in diabetic patients post-MI based on clinical evidence.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
